ObsEva SA (NASDAQ: OBSV) today announced the initiation of its international Phase 2a Proof-of-Concept clinical trial, PROLONG.The PROLONG trial is ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE